[go: up one dir, main page]

WO1995023580A1 - Prevention et traitement de la depilation secondaire - Google Patents

Prevention et traitement de la depilation secondaire Download PDF

Info

Publication number
WO1995023580A1
WO1995023580A1 PCT/JP1995/000350 JP9500350W WO9523580A1 WO 1995023580 A1 WO1995023580 A1 WO 1995023580A1 JP 9500350 W JP9500350 W JP 9500350W WO 9523580 A1 WO9523580 A1 WO 9523580A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair loss
administration
group
hair
copper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1995/000350
Other languages
English (en)
Japanese (ja)
Inventor
Katsumi Nogimori
Akio Terashima
Mikako Ohashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Procyte Corp
Original Assignee
Kaken Pharmaceutical Co Ltd
Procyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd, Procyte Corp filed Critical Kaken Pharmaceutical Co Ltd
Priority to AU18614/95A priority Critical patent/AU1861495A/en
Publication of WO1995023580A1 publication Critical patent/WO1995023580A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/58—Metal complex; Coordination compounds

Definitions

  • the present invention relates to an agent for preventing and treating secondary hair loss characterized by containing a tripeptide monocopper complex having an excellent effect in preventing and treating secondary hair loss induced by administration of an anticancer agent or the like.
  • An object of the present invention is to prevent and treat secondary hair loss, which is a side effect of chemotherapy or radiation therapy such as administration of an anticancer drug, more reliably.
  • the “secondary hair loss” in the present invention means a hair loss symptom secondary to a side effect caused by chemotherapy such as administration of an anticancer agent or radiation therapy.
  • chemotherapy such as administration of an anticancer agent or radiation therapy.
  • peptide-copper complexes have a hair growth-promoting effect on male pattern baldness, in which men lose their hair with age, but it has still been demonstrated that they are effective in secondary hair loss. Did not.
  • the present inventors thought that the peptide-copper complex was effective in preventing and treating secondary hair loss, and made extensive studies using a rat chemotherapy hair loss model.
  • FIG. 1 is a diagram showing the degree of hair loss of the whole body of the test substance-administered group, control group (vehicle-administered group), and normal group (anti-cancer drug-non-administered group) in Example 1 as a hair loss score as a criterion. It is.
  • FIG. 2 is a diagram showing animals in a test substance administration group on day 13 after the start of anticancer drug administration in Example 1.
  • FIG. 3 is a diagram showing animals in a control group on day 13 after the start of anticancer drug administration in Example 1.
  • FIG. 4 is a diagram showing animals in a normal group on day 13 after the start of anticancer drug administration in Example 1.
  • FIG. 5 is a diagram showing the degree of hair loss in the whole body of the test substance-administered group, the control group (vehicle-administered group), and the normal group (anti-cancer drug-non-administered group) in Example 2 as a hair loss score as a criterion. It is.
  • FIG. 6 is a diagram showing animals in a test substance administration group on day 14 after the start of anticancer drug administration in Example 2.
  • FIG. 7 is a diagram showing animals in a control group on day 14 after the start of anticancer drug administration in Example 2.
  • FIG. 8 is a diagram showing animals in the normal group on day 14 after the start of anticancer drug administration in Example 2.
  • Figure 9 shows the test substance-applied group and the control group (vehicle) on day 21 after hair removal in Example 3.
  • Fig. 2 shows the degree of hair loss of the animals in the application group) as a percentage of the area of hair removal relative to the area of hair removal.
  • FIG. 10 is a diagram showing the animals in the normal group (the group not administered with an anticancer drug) 21 days after hair removal in Example 3.
  • FIG. 11 shows the animals in the test substance application group 21 days after hair removal in Example 3.
  • FIG. 12 is a diagram showing animals of a control group (vehicle-applied group) 21 days after hair removal in Example 3.
  • the active ingredient of the present invention is a triptide copper complex represented by the general formula X: copper (II) (wherein X represents a tripeptide), and the constituent amino acids of tribetide are glycine, alanine, /, 'Lin, leucine, isoleucine, serine, threonine, cystine, cystine, methine, aspartic acid, glutamic acid, lysine, arginine, phenylalanine, tyrosine, histidine, tryptophan, proline, hydroxyproline, etc.
  • These amino acids can be prepared by a method described in JP-A-5-505808 by appropriately combining these three amino acids.
  • the amino acid may be either L-form or D-form.
  • L-alanyl-L-histidyl-L-lysine copper (11)
  • glycyl-L-histidyl L-lysine copper (11)
  • L-lysyl-L-histidyl-daricin complexes such as copper (II).
  • L-alanyl-L-histidyl-L-lysine copper (11)
  • glycyl-L-histidyl-L-lysine copper ( ⁇ )
  • L-aralanyl-L-histidyl-L —Lysine copper (II).
  • “copper ( ⁇ )” means a divalent copper ion, and is a tripeptide-copper (II) Although the molar ratio of tripeptide: copper ( ⁇ ) in the complex can be changed as appropriate, it is particularly preferably 1: 1 to 2: 1.
  • Particularly preferred tripeptide-copper (II) complexes include, for example, L-alanyl-L-histidyl L-lysine: copper ( ⁇ ) (1: 1), daricyl-L-histidyl L-lysine: copper (II) ( 1: 1), etc., and these triptotide-copper complexes can be used alone or as a mixture of two or more.
  • the agent for preventing or treating secondary hair loss of the present invention can be provided as a pharmaceutical, a quasi-drug, or a cosmetic, and its dosage form can be an intradermal injection or an external preparation.
  • bases such as creams, lotions, emulsions, ointments and gels can be used. If necessary, various preservatives, fragrances, stabilizers, coloring agents, humectants, thickeners, etc. Additives can also be added.
  • the amount of the secondary hair loss preventing / treating agent of the present invention can be appropriately changed depending on the kind of the drug used in the chemotherapy, the degree of the symptom, the dosage form, etc., but is usually about 0.001 to 10% by weight, preferably. Is incorporated in the preparation in an amount of about 0.01 to 5% by weight.
  • the dosage of the agent for preventing and treating secondary hair loss of the present invention usually varies depending on the administration method and dosage form, but is in the range of 0.1 to 4 ml per day for adults. This daily dose is administered once or several times a day. The daily dose may be larger than the above, if necessary.
  • the site of administration is preferably on the scalp.
  • Example 1 The test results of Example 1 are shown in FIG.
  • the whole body of the test substance-administered group, control group, and normal group animals 13 days after the start of anticancer drug administration is shown in FIGS. 2, 3, and 4, respectively.
  • Intradermal administration of L-alanyl-L-histidine-L-lysine Copper (II) (1: 1) 0.05 ml of a physiological saline solution containing 0.25% to one place at the center of the back of 8-day-old SD rats I do. From the next day, once a day, intraperitoneally administer Ar a-C at a dose of 25 mgZkg. The determination of the hair loss preventing effect was made by scoring the hair loss status of the whole body and the test substance administration site in the same manner as in Example 1. In the control group, only physiological saline was used.
  • Test results> The test results of Example 2 are shown in FIG.
  • test substance administration group of the present invention In the 0.25% test substance administration group of the present invention, almost the whole body hair excluding the administration site showed a hair loss pattern similar to that of the control group, but hair loss was prevented around the test substance administration site, and scars due to intradermal administration were observed. Was also not recognized.
  • FIGS. 6, 7, and 8 The whole body images of the test substance administration group, control group, and normal group animals on day 14 after the start of anticancer drug administration are shown in FIGS. 6, 7, and 8, respectively.
  • Example 1 and Example 2 the effect of preventing intradermal administration of the substance of the present invention for hair loss due to chemotherapy was clarified. Whether or not the application of the substance of the present invention exerts a hair loss preventing effect was examined using a mouse chemotherapy hair loss model.
  • FIG. 9 shows the hair removal rate of the test substance-applied group and the control group (vehicle-applied group) on day 21 after hair removal as a percentage of the hair removal area to the hair removal area.
  • the whole body images of the normal group (anticancer drug-free group), the test substance-applied group, and the control group (vehicle-applied group) on day 21 after hair removal are shown in FIGS. 10, 11, and 12, respectively.
  • the agent for preventing and treating secondary hair loss of the present invention is effective for secondary hair loss.
  • the preventive / therapeutic agent for secondary hair loss of the present invention is useful as a preventive and therapeutic agent for secondary hair loss that exhibits an excellent effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Prévention et traitement de la dépilation secondaire consécutive à une chimiothérapie à base de carcinostatiques ou à une radiothérapie, au moyen d'un complexe de tripeptide de cuivre de formule générale X:Cu(II) où X est un tripeptide.
PCT/JP1995/000350 1994-03-03 1995-03-03 Prevention et traitement de la depilation secondaire Ceased WO1995023580A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU18614/95A AU1861495A (en) 1994-03-03 1995-03-03 Preventive and remedy for secondary depilation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6/58188 1994-03-03
JP5818894 1994-03-03

Publications (1)

Publication Number Publication Date
WO1995023580A1 true WO1995023580A1 (fr) 1995-09-08

Family

ID=13077053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1995/000350 Ceased WO1995023580A1 (fr) 1994-03-03 1995-03-03 Prevention et traitement de la depilation secondaire

Country Status (2)

Country Link
AU (1) AU1861495A (fr)
WO (1) WO1995023580A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504063A (ja) * 2001-09-03 2005-02-10 リシャール・ヴェルミー 化学療法誘導性脱毛の予防に関連する組成物および方法
JP2006504448A (ja) * 2002-07-02 2006-02-09 プロサイト コーポレイション ペプチド銅錯体および軟組織充填物を含有する組成物
JP2007516209A (ja) * 2003-07-18 2007-06-21 アンスティテュ・ヨーロペアン・ドゥ・ビョロジ・セリュレール 脱毛症の予防および治療的処置用組成物の製造のためのペプチド複合体の使用
WO2021247531A1 (fr) * 2020-06-01 2021-12-09 Balchem Corporation Chélates métalliques de diaminoacide ou chélates métalliques de triaminoacide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05501567A (ja) * 1989-11-13 1993-03-25 プロサイト　コーポレーション 毛髪成長を刺激するための金属―ペプチド組成物及び方法
JPH06305941A (ja) * 1993-04-15 1994-11-01 Procyte Corp 毛の成長を促進する医薬及び化粧品

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05501567A (ja) * 1989-11-13 1993-03-25 プロサイト　コーポレーション 毛髪成長を刺激するための金属―ペプチド組成物及び方法
JPH06305941A (ja) * 1993-04-15 1994-11-01 Procyte Corp 毛の成長を促進する医薬及び化粧品

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504063A (ja) * 2001-09-03 2005-02-10 リシャール・ヴェルミー 化学療法誘導性脱毛の予防に関連する組成物および方法
JP2006504448A (ja) * 2002-07-02 2006-02-09 プロサイト コーポレイション ペプチド銅錯体および軟組織充填物を含有する組成物
JP2007516209A (ja) * 2003-07-18 2007-06-21 アンスティテュ・ヨーロペアン・ドゥ・ビョロジ・セリュレール 脱毛症の予防および治療的処置用組成物の製造のためのペプチド複合体の使用
JP2013010769A (ja) * 2003-07-18 2013-01-17 Inst Europeen De Biologie Cellulair 脱毛症の予防および治療的処置用組成物の製造のためのペプチド複合体の使用
JP2015134777A (ja) * 2003-07-18 2015-07-27 アンスティテュ・ヨーロペアン・ドゥ・ビョロジ・セリュレールＩｎｓｔｉｔｕｔ Ｅｕｒｏｐｅｅｎ Ｄｅ Ｂｉｏｌｏｇｉｅ Ｃｅｌｌｕｌａｉｒｅ 脱毛症の予防および治療的処置用組成物の製造のためのペプチド複合体の使用
WO2021247531A1 (fr) * 2020-06-01 2021-12-09 Balchem Corporation Chélates métalliques de diaminoacide ou chélates métalliques de triaminoacide

Also Published As

Publication number Publication date
AU1861495A (en) 1995-09-18

Similar Documents

Publication Publication Date Title
JP4352114B2 (ja) 有益な効果を奏するアルギニンの投薬
US9333156B2 (en) External preparation for skin
US8183204B2 (en) Methods and compositions for increasing skin remodeling
US9782438B2 (en) Method of promoting hair growth by administration of BFGF
JP2002515401A5 (fr)
KR20060028401A (ko) 적비(赤鼻) 치료용 조성물 및 치료 방법
KR20060007040A (ko) 건선 치료용 조성물 및 치료방법
JP2731976B2 (ja) 皮膚の微小循環に対して作用する薬剤組成物
ES2279624T3 (es) Tratamiento de contacto breve del acne y fotoenvejecimiento con retinoides topicos.
US20120083452A1 (en) Topical Anesthetic Uses of Szeto-Schiller Peptides
KR20050072799A (ko) 펩티드 구리 착물과 미녹시딜을 함유하는 조성물에 의한모발 성장의 자극
JP2000038340A (ja) 育毛剤および食品
JPH1059829A (ja) 養毛剤
CN102791284A (zh) 治疗或预防毛发脱落或促进毛发生长的方法
WO1995023580A1 (fr) Prevention et traitement de la depilation secondaire
JP2018519350A (ja) 化学療法に関連する脱毛の軽減方法
US20050276766A1 (en) Methods and compositions for increasing skin remodeling
JPWO1995023580A1 (ja) 二次性脱毛予防・治療剤
US11642328B2 (en) Creatine, its derivatives, compositions and methods of use thereof
KR100308491B1 (ko) 모발 성장 조성물
JPH10265365A (ja) ニキビ用皮膚外用剤
Durivage et al. Prevention and management of toxicities associated with antineoplastic drugs
WO2000067699A3 (fr) Compositions pharmaceutiques pour traiter le paludisme
JPH02501570A (ja) 脱毛症を治療するためのニコランジルの使用
JPH0232007A (ja) 養毛剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KG KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA